No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

US Patent Issued to REVIAN® Duel Band LED Light Therapy

Editor: What To Know

  • The claims in this issued patent cover the use of specific wavelengths of LED light to stimulate the body's cellular generation of nitric oxide as well as to release the body's natural nitric oxide reserves.
  • Nitric oxide has a remarkably diverse range of biological functions as it is involved in the proper function of virtually every organ in the human body, and its decline is linked to many degenerative diseases of aging.
  • “By stimulating the body's internal mechanisms for the generation and release of nitric oxide, we are able to realize the therapeutic benefits of nitric oxide in the body without the challenges of pharmaceutical drug development,” continued Dr.

The United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,265,258 – the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the body.

“This is a groundbreaking approach to the therapeutic use of light,” said Dr. Nathan Stasko, co-inventor and Executive Chairman REVIAN Inc. “We set out to decode the spectrum of light and identify which wavelengths encourage cells, tissues and organs to repair themselves.”

The claims in this issued patent cover the use of specific wavelengths of LED light to stimulate the body’s cellular generation of nitric oxide as well as to release the body’s natural nitric oxide reserves. Nitric oxide has a remarkably diverse range of biological functions as it is involved in the proper function of virtually every organ in the human body, and its decline is linked to many degenerative diseases of aging.

“By stimulating the body’s internal mechanisms for the generation and release of nitric oxide, we are able to realize the therapeutic benefits of nitric oxide in the body without the challenges of pharmaceutical drug development,” continued Dr. Stasko.

The assembly of such an experienced team in both LED and medical discovery to address the needs of the body is unprecedented. The group of inventors listed on the patent represents the same fusion of life science and light science that their invention embodies. Among them, this group has over 500 patent filings and over 250 issued patents, the bulk of which can be attributed to Gerry Negley, co-inventor and arguably the foremost expert on the creation and delivery of LED light. He is inventor or co-inventor on about every major advancement in LED-based light. Now REVIAN, and its parent company KNOW Bio, are unleashing the power of LED technology to create optimum biological outcomes.

“The body’s natural capabilities to heal and regenerate itself can be unlocked using light,” said Gerry Negley. “With this technology, we are doing just that by using a proprietary combination of monochromatic LEDs.”

Medical LED systems are possible because of the decades of innovation in semiconductor materials that have now created the ability for light to be delivered in precise, narrow bands that lead to direct engagement of biological tissues. With power levels at or exceeding the output of lasers, higher efficiency LEDs enable devices that are durable, smaller, lightweight and far more comfortable and convenient for people to use.

REVIAN RED is the first product to employ the therapeutic advances enabled by combining LED technology and nitric oxide medical research. This advanced medical device is clinically proven to stop hair loss and grow new hair, providing a potentially life-changing treatment for men and women suffering from androgenetic alopecia.

“Our patented dual-band technology can give new hope to the estimated 50 million men and 30 million women suffering from androgenetic hair loss in the United States and to hundreds of millions more around the globe,” said Brian Johnson, President REVIAN Inc. “When you add a second wavelength and use LEDs to provide a whole new patient experience designed from the ground up to be comfortable, effective, safe and convenient—you have REVIAN RED, the most technologically advanced answer for these millions of sufferers.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy